证券代码：600058 证券简称：五矿发展 公告编号：临2025-71 债券代码：242936 债券简称：25发展Y1 债券代码：243004 债券简称：25发展Y3 债券代码：243237 债券简称：25发展Y4 五矿发展股份有限公司 第十届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 五矿发展股份有限公司（以下简称"公司"）第十届董事会第十一次会议于2025年12月22日以通讯方式召 开。会议通知于2025年12月18日以专人送达、邮件的方式向全体董事发出。本次会议应出席会议董事9 人，实际出席会议董事9人。本次会议由公司董事长魏涛先生主持。本次会议的召开符合《中华人民共 和国公司法》等有关法律、行政法规、部门规章、规范性文件和《公司章程》等有关规定。 二、董事会会议审议情况 本次会议审议并通过《关于公司与关联方续签〈金融服务协议〉的议案》。 同意公司与五矿集团财务有限责任公司续签《金融服务协议》。 上述事项已经公司独立董事专门会议审议通过，同意提交公司董事会审议。 本 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002983 证券简称：芯瑞达 公告编号：2025-078 安徽芯瑞达科技股份有限公司 关于召开2026年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要提示： 一、召开会议的基本情况 1、股东会届次：2026年第一次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市规则》《深圳证 券交易所上市公司自律监管指引第1号一一主板上市公司规范运作》等法律、行政法规、部门规章、规 范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2026年01月09日14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为2026年01月09日9:15-9:25， 9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票的具体时间为2026年01月09日9:15 至15:00的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：202 ...

重要内容提示： ● 担保对象及基本情况 ■ 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 ● 累计担保情况 ■ 青岛汇金通电力设备股份有限公司（以下简称"公司"）于2025年12月22日与苏州银行股份有限公司兴化 支行（以下简称"苏州银行"）签订《最高额保证合同》，为下属控股子公司江苏江电电力设备有限公司 （以下简称"江苏江电"）申请银行综合授信提供人民币8000万元担保，担保方式为连带责任保证。截至 本公告披露日，公司年度预计担保额度使用情况如下： 单位：万元 ■ （二）内部决策程序 公司于2025年3月24日召开第五届董事会第二次会议、2025年4月14日召开2024年年度股东大会分别审议 通过了《关于2025年公司及子公司间担保额度预计的议案》，同意2025年度公司为合并报表范围内下属 子公司提供担保、子公司间互相担保额度总计不超过人民币11亿元（包括原有担保展期或续保）,担保 方式包括保证、抵押、质押等。具体内容详见公司于2025年3月25日在上海证券交易所 （www.sse.com.cn）披露的《公司关于2025年 ...

Group 1 - The fund is currently in its twentieth closed period, which will end on December 23, 2025, and will enter an open period from December 24, 2025, to January 22, 2026, during which subscription and redemption services can be processed [1][3] - The minimum subscription amount is set at 1,000 yuan for direct sales and 1 yuan for online platforms, with specific requirements depending on the sales institution [4] - The A-class fund shares will incur a subscription fee, while C-class shares will not charge any subscription fee, with the fees primarily covering marketing and sales expenses [5][6] Group 2 - Redemption requests must be at least 100 shares, and if the remaining balance after redemption is less than 100 shares, the entire amount must be redeemed [9] - The redemption fee for A-class shares is 1.5% if held for less than 7 days, while other cases incur no fee, with the fees being fully allocated to the fund's assets [10] - The fund management can adjust fees or methods within the contract's scope and must announce any changes in advance [11] Group 3 - The fund will disclose its net asset value at least weekly during the closed period and no later than the next day during the open period [19] - Investors are encouraged to read the fund's prospectus and updates for detailed information [20] - The fund was renamed from Hua Fu Chang Le Semi-Annual Open Bond Fund to Xing Yin Chang Le Semi-Annual Open Bond Fund on April 5, 2017 [20]

Group 1: Company Culture and Values - Company emphasizes the importance of corporate culture as the soul of the enterprise, promoting values such as integrity, innovation, and collaboration [1] - The core value of the company is summarized as "profit through righteousness, cooperation and inclusiveness, and pursuit of excellence" [1] Group 2: Strategic Development - The company has identified "serving the real economy" and "differentiated development" as its two main strategic lines since the beginning of the 13th Five-Year Plan [2] - A dedicated working group was established in 2016 to enhance services for the real economy, covering a comprehensive service system for various financial needs [2] - The company has achieved significant market presence, serving over 90% of large state-owned enterprises in Shanxi and completing numerous benchmark projects [2] Group 3: Financial Services and Innovations - The company is committed to high-quality development, focusing on enhancing the professionalism and sustainability of financial services [3] - A three-year action plan (2025-2027) has been established to implement the "Five Major Financial Articles" strategy, aligning with Shanxi's energy transition and industrial upgrading [3] - The company has developed a green finance service system, including innovative products like low-carbon transition bonds and green ABS [4][5] Group 4: Support for Technological and Traditional Industries - The company has issued 12 technology innovation bonds totaling 11.8 billion yuan to support local enterprises in their technological advancements [7] - It actively promotes the integration of technology finance and inclusive finance to support small and medium-sized enterprises [8] - The company has established a fund management role for the provincial angel fund, focusing on strategic emerging industries such as new energy and biomedicine [8] Group 5: Commitment to National Strategy - The company aligns its operations with the national strategy outlined in the 14th Five-Year Plan, emphasizing the construction of a modern industrial system and the strengthening of the real economy [6][9] - It aims to enhance its role in capital market reforms and high-quality development, contributing to the construction of a financial power [9][10]

Fund Overview - The fund is named Qianhai Kaiyuan Xinghe Bond Fund, registered with the China Securities Regulatory Commission (CSRC) on July 5, 2025 [1] - The fund is a contract-based open-end bond investment fund managed by Qianhai Kaiyuan Fund Management Co., Ltd. and custodied by Industrial Bank Co., Ltd. [1][11] Fundraising Details - The initial fundraising cap is set at 5 billion RMB, excluding interest accrued during the fundraising period [2] - If the total effective subscription amount exceeds 5 billion RMB, the fund manager will implement a proportional confirmation method to control the scale [2][3] - The fundraising period is from December 31, 2025, to March 30, 2026, with the possibility of adjustments based on subscription conditions [1][12] Subscription Regulations - The minimum subscription amount for both initial and additional subscriptions is 10 RMB, including subscription fees [2] - There is no limit on the cumulative subscription amount for individual investors, but no single investor can hold more than 50% of the fund's shares [3][11] - The fund allows multiple subscriptions during the fundraising period, and subscription fees will be calculated separately for each application [22] Investment Strategy - The fund will invest in various securities, including asset-backed securities and government bond futures, which may introduce additional risks [6][7] - The fund may also invest in stocks listed on the Hong Kong Stock Exchange under the Stock Connect mechanism, facing unique risks associated with this market [7] Fund Management and Operations - The fund management will adhere to principles of diligence, honesty, and prudence, but does not guarantee profits or minimum returns [6] - The fund's performance may be influenced by the performance of other funds it invests in, as well as the management quality of those funds [8] Investor Information - Investors can contact the fund management company for subscription inquiries and assistance [4] - The fund's detailed information, including the prospectus and fund contract, will be available on the fund management company's website and the CSRC's electronic disclosure website [3]

Group 1 - The article discusses the importance of social insurance in China, highlighting its role in providing lifelong security for individuals [1] - It emphasizes the growth and development of China's social insurance system, which is crucial for the country's social stability and economic progress [1] - The article mentions specific statistics related to the coverage and benefits of social insurance, indicating a significant increase in participation rates [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 HS387片是一款由公司自主研发的选择性KIF18A抑制剂，拟用于高级别浆液性卵巢癌、非小细胞肺癌 等晚期实体瘤治疗。该药品已经获得国家药品监督管理局颁发的《药物临床试验批准通知书》，详见公 司于2025年7月2日披露的《关于获得药物临床试验批准通知书的公告》（公告编号：临2025-37号）。 2025年11月，公司完成向美国FDA递交HS387片的临床试验申请，并于近日获得FDA批准。截至目前， 国内外有多款KIF18A抑制剂进入临床研发阶段，目前尚无药物上市。 近日，浙江海正药业股份有限公司（以下简称"公司"）收到美国食品药品监督管理局（以下简称"美国 FDA"）的通知，由公司申报的HS387片药品临床试验申请已获得美国FDA批准，可以在美国开展临床 试验。现就相关情况公告如下： 一、药品基本情况 药品名称：HS387片 IND编号：IND 178632 申请事项：新药临床试验申请 申请人：浙江海正药业股份有限公司 二、该药品研发及相关情况 董事会 二○二五年十二月二十三日 ...

Summary of Key Points Core Viewpoint - The announcement details the share pledge situation of Hengli Petrochemical Co., Ltd., indicating that the controlling shareholder, Hengli Group, and its concerted parties hold a significant portion of shares, with a notable amount pledged for liquidity purposes [1][3]. Share Pledge Situation - Hengli Group and its concerted parties currently hold a total of 5,310,675,080 shares, representing 75.45% of the company, with 1,686,200,000 shares pledged, accounting for 31.75% of their holdings and 23.95% of the total share capital [1][3]. - Hengneng Investment holds 1,498,478,926 shares, which is 21.29% of the company, with 578,200,000 shares pledged, making up 38.59% of its holdings and 8.21% of the total share capital [1][3]. Purpose and Impact of Pledge - The shares pledged by Hengneng Investment are intended to supplement liquidity, with the main debt obligation maturing on January 22, 2027 [1][2]. - The pledged shares are not used for restructuring performance compensation or other guarantees, indicating a focused purpose for the pledge [2]. - Hengneng Investment is reported to have a good credit status and repayment capability, suggesting that the pledge risk is manageable and will not lead to a change in actual control of the company [3].

特此公告。 深圳市安奈儿股份有限公司董事会 关于完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 深圳市安奈儿股份有限公司（以下简称"公司"）于2025年10月28日召开第四届董事会第二十三次会议、 2025年11月14日召开2025年第二次临时股东大会，审议通过了《关于修订〈公司章程〉并取消监事会的 议案》，同意对《公司章程》进行修订并取消监事会，由董事会审计委员会行使《中华人民共和国公司 法》规定的监事会职权。具体内容详见公司分别于2025年10月29日、2025年11月14日在巨潮资讯网 （http://www.cninfo.com.cn）上披露的《第四届董事会第二十三次会议决议公告》（公告编号：2025- 054）、《关于修订〈公司章程〉、取消监事会、修订公司部分治理制度的公告》（公告编号：2025- 057）、《2025年第二次临时股东大会决议公告》（公告编号：2025-060）。 公司已于2025年12月22日完成上述事项的工商变更登记和章程备案手续，并取得了由深圳市市场监督管 理局出具的《登记通知书》。本次变更备案不涉及换发 ...